| ［1］ |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229–263.
|
| ［2］ |
Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3): 233–254.
|
| ［3］ |
Sun Q, Hong Z, Zhang C, et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends[J]. Signal Transduct Target Ther, 2023, 8(1): 320.
|
| ［4］ |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207–2218.
|
| ［5］ |
Taieb J, Ambrosini M, Alouani E, et al. Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors[J]. J Immunother Cancer, 2025, 13(1): e010424.
|
| ［6］ |
Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR/MSI-H solid tumors[J]. Trends Cancer, 2023, 9(10): 828–839.
|
| ［7］ |
Sinicrope FA, Ou FS, Arnold D, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage Ⅲ deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)[J]. J Clin Oncol, 2025, 43(suppl_17): LBA1.
|
| ［8］ |
饶佳伟, 许诗语, 陈创奇. 2024年度结直肠癌治疗研究进展[J/CD]. 消化肿瘤杂志(电子版), 2025, 17(2): 182–188.
|
| ［9］ |
Chalabi M, Verschoor YL, Tan PB, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer[J]. N Engl J Med, 2024, 390(21): 1949–1958.
|
| ［10］ |
Ludford K, Ho WJ, Thomas JV, et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors[J]. J Clin Oncol, 2023, 41(12): 2181–2190.
|
| ［11］ |
de Gooyer PGM, Verschoor YL, van den Dungen LDW, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: A phase 2 trial[J]. Nat Med, 2024, 30(11): 3284–3290.
|
| ［12］ |
Andre T, Elez E, Van Cutsem E, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer[J]. N Engl J Med, 2024, 391(21): 2014–2026.
|
| ［13］ |
Buchler T. Microsatellite instability and metastatic colorectal cancer–a clinical perspective[J]. Front Oncol, 2022, 12: 888181.
|
| ［14］ |
Abildgaard AB, Nielsen SV, Bernstein I, et al. Lynch syndrome, molecular mechanisms and variant classification[J]. Br J Cancer, 2023, 128(5): 726–734.
|
| ［15］ |
Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895–2015[J]. Nat Rev Cancer, 2015, 15(3): 181–194.
|
| ［16］ |
Winer A, Ghatalia P, Bubes N, et al. Dual checkpoint inhibition with ipilimumab plus nivolumab after progression on sequential PD-1/PDL-1 inhibitors pembrolizumab and atezolizumab in a patient with Lynch syndrome, metastatic colon, and localized urothelial cancer[J]. Oncologist, 2019, 24(11): 1416–1419.
|
| ［17］ |
Eslinger C, Walden D, Barry T, et al. Rechallenge with switching immune checkpoint inhibitors following autoimmune myocarditis in a patient with Lynch syndrome[J]. J Natl Compr Canc Netw, 2023, 21(9): 894–899.
|
| ［18］ |
Pellat A, Loisel C, Metras J, et al. Occurrence of dMMR/MSI-H tumor during follow-up in Lynch syndrome patients treated with immune checkpoint inhibitors for metastatic digestive cancer between 2015 and 2024: A retrospective analysis of a monocentric prospective cohort study[J]. ESMO open, 2025, 10(9): 105559.
|
| ［19］ |
Yamaguchi K, Tsuchihashi K, Ueno S, et al. Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes[J]. Esmo Open, 2025, 10(1): 104108.
|
| ［20］ |
饶佳伟, 陈创奇. 晚期结直肠癌免疫治疗现状与挑战[J/CD]. 消化肿瘤杂志(电子版), 2024, 16(3): 284–290.
|
| ［21］ |
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment[J]. Nat Rev Cancer, 2012, 12(4): 237–251.
|
| ［22］ |
Lentz RW, Friedrich TJ, Blatchford PJ, et al. A phase Ⅱ study of potentiation of pembrolizumab with binimetinib and bevacizumab in refractory microsatellite-stable colorectal cancer[J]. Clin Cancer Res, 2024, 30(17): 3768–3778.
|
| ［23］ |
Mettu NB, Ou FS, Zemla TJ, et al. Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: A randomized clinical trial[J]. JAMA Netw Open, 2022, 5(2): e2149040.
|
| ［24］ |
Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study[J]. J Clin Oncol, 2024, 42(22): 2637–2644.
|
| ［25］ |
Saeed A, Park R, Pathak H, et al. Clinical and biomarker results from a phase Ⅱ trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort[J]. Nat Commun, 2024, 15(1): 1533.
|
| ［26］ |
Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications[J]. Sci Immunol, 2016, 1(3): eaag1266.
|
| ［27］ |
Parikh AR, Szabolcs A, Allen JN, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase Ⅱ trial[J]. Nat Cancer, 2021, 2(11): 1124–1135.
|
| ［28］ |
Rao J, Chen Z, Wang Z, et al. 120TiP neoadjuvant short-course radiotherapy combined with chemotherapy and cadonilimab for patients with locally advanced rectal cancer: A prospective, single-arm phase Ⅱ trial[J]. Ann Oncol, 2024, 35(Suppl_4): S1447.
|
| ［29］ |
Frentzas S, Mislang ARA, Lemech C, et al. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors[J]. J Immunother Cancer, 2024, 12(4): e008037.
|
| ［30］ |
Fang W, Zhao Y, Luo Y, et al. Ivonescimab plus chemotherapy in non–small cell lung cancer with EGFR variant: A randomized clinical trial[J]. Jama, 2024, 332(7): 561–570.
|
| ［31］ |
Ghanbari Sevari F, Mehdizadeh A, Abbasi K, et al. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies[J]. Stem Cell Res Ther, 2024, 15(1): 254.
|
| ［32］ |
Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors[J]. J Cancer, 2011, 2: 363.
|
| ［33］ |
Fayyaz F, Yazdanpanah N, Rezaei N. Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer[J]. Cell Commun Signal, 2022, 20(1): 41.
|
| ［34］ |
Li CMY, Tomita Y, Dhakal B, et al. Use of cytokine-induced killer cell therapy in patients with colorectal cancer: A systematic review and meta-analysis[J]. J Immunother Cancer, 2023, 11(4): e006764.
|
| ［35］ |
Chen N, Pu C, Zhao L, et al. Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: A nonrandomized clinical trial[J]. JAMA Oncol, 2024, 10(11): 1532–1536.
|
| ［36］ |
Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer[J]. Science, 2015, 348(6230): 62–68.
|
| ［37］ |
Amaria R, Knisely A, Vining D, et al. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma[J]. J Immunother Cancer, 2024, 12(2): e006822.
|
| ［38］ |
Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer[J]. N Engl J Med, 2016, 375(23): 2255–2262.
|
| ［39］ |
Lu Y, Ma S, Ding W, et al. Resident immune cells of the liver in the tumor microenvironment[J]. Front Oncol, 2022, 12: 931995.
|
| ［40］ |
Baek J, Choi G, Lee GH, et al. Characteristics of successful expansion of tumor-infiltrating lymphocytes from colorectal cancer liver metastasis[J]. Sci Rep, 2025, 15(1): 1639.
|
| ［41］ |
Liu C, Liu N, Zhang T, et al. Adoptive immune cell therapy for colorectal cancer[J]. Front Immunol, 2025, 16: 1557906.
|
| ［42］ |
Wermke M, Araurjo DM, Chatterjee M, et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: A phase 1 trial[J]. Nat Med, 2025, 31(7): 2365–2374.
|
| ［43］ |
Maggadottir SM, Dueland S, Mensali N, et al. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer[J]. Mol Ther, 2024, 32(6): 2021–2029.
|
| ［44］ |
Saxena M, van der Burg SH, Melief CJM, et al. Therapeutic cancer vaccines[J]. Nat Rev Cancer, 2021, 21(6): 360–378.
|
| ［45］ |
Rodriguez J, Castañón E, Perez-Gracia JL, et al. A randomized phase Ⅱ clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis[J]. J Immunother Cancer, 2018, 6(1): 96.
|
| ［46］ |
Español-Rego M, Fernández-Martos C, Elez E, et al. A phase Ⅰ-Ⅱ multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study[J]. Cancer Immunol Immunother, 2023, 72(4): 827–840.
|
| ［47］ |
Snook AE, Baybutt TR, Xiang B, et al. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients[J]. J Immunother Cancer, 2019, 7(1): 104.
|
| ［48］ |
Crosby EJ, Hobeika AC, Niedzwiecki D, et al. Long-term survival of patients with stage Ⅲ colon cancer treated with VRP-CEA (6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio[J]. J Immunother Cancer, 2020, 8(2): e001662.
|
| ［49］ |
Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022.
|
| ［50］ |
Taniguchi H, Iwasa S, Yamazaki K, et al. Phase 1 study of OCV‐C02, a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer[J]. Cancer Sci, 2017, 108(5): 1013–1021.
|
| ［51］ |
Hubbard JM, Tőke ER, Moretto R, et al. Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: An open-label, multicenter, phase Ⅰb study[J]. Clin Cancer Res, 2022, 28(13): 2818–2829.
|